{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:40:38Z","timestamp":1776084038905,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T00:00:00Z","timestamp":1475193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Papillomavirus Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pvr.2017.03.001","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T17:32:41Z","timestamp":1489685561000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Incidence rates of Guillain Barr\u00e9 (GBS), chronic fatigue\/systemic exertion intolerance disease (CFS\/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002\u20132012"],"prefix":"10.1016","volume":"3","author":[{"given":"J.","family":"Skufca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ollgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ruokokoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Lyytik\u00e4inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Nohynek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"89","key":"10.1016\/j.pvr.2017.03.001_bib1","first-page":"465","article-title":"Human papillomavirus vaccines: WHO position paper","volume":"43","author":"World Health Organization","year":"2014","journal-title":"Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.pvr.2017.03.001_bib2","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted L1 VLP vaccine against infection with HPV16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pvr.2017.03.001_bib3","first-page":"1915","article-title":"Efficacy of a quadrivalent HPV types 8\/11\/16\/18) L1 virus-like particle vaccine in the prevention of cervical intraepithelial neoplasia grades 2\/3 and adenocarcinoma in situ: a randomized controlled trial","volume":"356","author":"Villa","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pvr.2017.03.001_bib4","unstructured":"National Institute for Health and Welfare (THL), Department of Vaccination and Immune Protection. HPV vaccination coverage in Finland; 2016 . (Accessed 11 April 2016)."},{"key":"10.1016\/j.pvr.2017.03.001_bib5","unstructured":"Finnish Medicines Agency (Fimea). Question E 9\/2015 from the Nordic Council regarding adverse reactions to HPV-vaccine. Contribution from Finland to the question from the Nordic Council; 3 Nov 2015."},{"key":"10.1016\/j.pvr.2017.03.001_bib6","doi-asserted-by":"crossref","unstructured":"D. Descamps, K. Hardt, B. Spiessens, et al. Safety of human papillomavirus (HPV)-16\/18 AS04 adjuvanted vaccine for cervical cancer prevention: integrated summary of 11 clinical trials.\u00a026th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID), Austria: Graz; 13\u201316 May, 2008.","DOI":"10.4161\/hv.5.5.7211"},{"key":"10.1016\/j.pvr.2017.03.001_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/INF.0b013e3181b77906","article-title":"Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine","volume":"29","author":"Block","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.pvr.2017.03.001_bib8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pds.3593","article-title":"Post-licensure safety surveillance for human papillomavirus-16\/18-AS04-adjuvanted vaccine: more than 4\u2008years of experience","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"10.1016\/j.pvr.2017.03.001_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-013-0039-5","article-title":"Safety of human papillomavirus vaccines: a review","volume":"36","author":"Macartney","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.pvr.2017.03.001_bib10","unstructured":"European Medicines Agency (EMA), Periodic safety update reports, \u3008http:\/\/www.ema.europa.eu\/ema\/index.jsp?Curl=pages\/regulation\/document_listing\/document_listing_000361.jsp\u3009 ; 2016. (Accessed 21 June 2016)."},{"key":"10.1016\/j.pvr.2017.03.001_bib11","unstructured":"European Medicines Agency (EMA), Assessment report. Human papillomavirus (HPV) vaccines, \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/HPV_vaccines_20\/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use\/WC500197129.pdf\u3009; Nov 11 2015. (Accessed 11 May 2016)."},{"key":"10.1016\/j.pvr.2017.03.001_bib12","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstr\u00f6m","year":"2013","journal-title":"Br. Med. J."},{"key":"10.1016\/j.pvr.2017.03.001_bib13","unstructured":"Ministry of Social Affairs and Health, Finland. Communicable Diseases Act. No. 583\/1986, \u3008http:\/\/www.finlex.fi\/fi\/laki\/kaannokset\/1986\/en19860583.pdf\u3009; 25 Jul 1986 . (Accessed 25 May 2016)."},{"key":"10.1016\/j.pvr.2017.03.001_bib14","unstructured":"National Institute for Health and Welfare (THL), Department of Vaccination and Immune Protection. Register of adverse effects of vaccines. April 2016."},{"key":"10.1016\/j.pvr.2017.03.001_bib15","unstructured":"Global Advisory Committee on Vaccine Safety (GACVS), Weekly epidemiological record. No. 7, 2014, 89, 53\u201360, \u3008http:\/\/www.who.int\/vaccine_safety\/committee\/reports\/wer8907.pdf?ua=1\u3009; 11\u201312 December 2013. (Accessed 11 April 2016)."},{"key":"10.1016\/j.pvr.2017.03.001_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.pvr.2017.03.001_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000184748","article-title":"The epidemiology of Guillain-Barr\u00e9 syndrome worldwide. A systematic literature review","volume":"32","author":"McGrogan","year":"2009","journal-title":"Neuroepidemiology"},{"issue":"22","key":"10.1016\/j.pvr.2017.03.001_bib18","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.vaccine.2009.02.106","article-title":"Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events","volume":"27","author":"Callr\u00e9us","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.03.001_bib19","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barr\u00e9 syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pvr.2017.03.001_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12883-016-0598-z","volume":"16","author":"Alcalde-Cabero","year":"2016","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.pvr.2017.03.001_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10654-015-0047-0","article-title":"Risk of Guillain-Barr\u00e9 syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study","volume":"31","author":"Ghaderi","year":"2016","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.pvr.2017.03.001_bib22","series-title":"Adverse Effects of Vaccines: Evidence and Causality","article-title":"Institute of Medicine","author":"Committee to Review Adverse Effects of Vaccines","year":"2011"},{"key":"10.1016\/j.pvr.2017.03.001_bib23","unstructured":"French medicines agency (ANSM), Vaccins anti-HPV et risque de maladies auto-immunes: \u00e9tude pharmaco-\u00e9pid\u00e9miologique - Rapport final - Septembre 2015, \u3008file:\/\/\/C:\/Users\/jkue\/AppData\/Local\/Temp\/Ansm_Gardasil-Hpv2_Rapport_Septembre-2015.pdf\u3009; 14 Sept 2015."},{"key":"10.1016\/j.pvr.2017.03.001_bib24","first-page":"167","article-title":"Two age peaks in the incidence of chronic fatigue syndrome\/myalgic encephalomyelitis: a population-based registry study from Norway 2008\u20132012","volume":"12","author":"Bakken","year":"2014","journal-title":"BMC Med."},{"key":"10.1016\/j.pvr.2017.03.001_bib25","unstructured":"Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Beyond Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome: Redefining an Illness. Washington (DC): National Academies Press (US); \u3008http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK284897\/\u3009; 10 Feb 2015."},{"issue":"46","key":"10.1016\/j.pvr.2017.03.001_bib26","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1016\/j.vaccine.2015.10.018","article-title":"Chronic fatigue syndrome\/myalgic encephalomyelitis (CFS\/SEID\/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine","volume":"33","author":"Magnus","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.03.001_bib27","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1016\/j.vaccine.2013.08.024","article-title":"Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK","volume":"31","author":"Donegan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.03.001_bib28","unstructured":"R. Wilson, P. Paterson, J. Chiu, W. Schulz, H. Larson, HPV Vaccination in Japan. The continuing debate and Global Impacts. A Report of the CSIS Global Health Policy Center 2015, \u3008http:\/\/csis.org\/files\/publication\/150422_Wilson_HPVVaccination2_Web.pdf\u3009; April 2015. (Accessed 16 May 2016)."},{"issue":"19","key":"10.1016\/j.pvr.2017.03.001_bib29","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.2169\/internalmedicine.53.3133","article-title":"Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine","volume":"53","author":"Kinoshita","year":"2014","journal-title":"Intern. Med."},{"issue":"1","key":"10.1016\/j.pvr.2017.03.001_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/ene.12272","article-title":"Postural tachycardia syndrome following human papillomavirus vaccination","volume":"21","author":"Blitshteyn","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"22","key":"10.1016\/j.pvr.2017.03.001_bib31","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.vaccine.2015.03.098","article-title":"Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus","volume":"33","author":"Brinth","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.03.001_bib32","unstructured":"European Medicines Agency, EMA to further clarify safety profile of human papillomavirus (HPV) vaccines. \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/HPV_vaccines_20\/Procedure_started\/WC500189476.pdf\u3009; 13 July 2015. (Accessed 16 April 2016)."},{"key":"10.1016\/j.pvr.2017.03.001_bib33","unstructured":"Global Advisory Committee on Vaccine Safety (GACVS). Statement on Safety of HPV vaccines, \u3008http:\/\/www.who.int\/vaccine_safety\/committee\/GACVS_HPV_statement_17Dec2015.pdf;17\u3009 December 2015 . (Accessed 21 May 2016)."},{"key":"10.1016\/j.pvr.2017.03.001_bib34","unstructured":"Nordic Cochrane Centre. Complaint to the European Medicines Agency (EMA) over maladministration at the EMA, \u3008http:\/\/nordic.cochrane.org\/sites\/nordic.cochrane.org\/files\/uploads\/ResearchHighlights\/Complaint-to-EMA-over-EMA.pdf\u3009; 26 May 2016. (Accessed 16 June 2016)."},{"key":"10.1016\/j.pvr.2017.03.001_bib35","unstructured":"Statens Serum Institute. Annual reports on the Danish childhood vaccination programme, \u3008http:\/\/www.ssi.dk\/English\/News\/EPI-NEWS\/2016\/No%2017%20-%202016.aspx\u3009; 27 April 2016. (Accessed 12 May 2016)."},{"key":"10.1016\/j.pvr.2017.03.001_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ebiom.2016.08.042","article-title":"The state of vaccine confidence 2016: global insights through a 67-country survey","volume":"12","author":"Larson","year":"2016","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.pvr.2017.03.001_bib37","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"ASO3 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS One"}],"container-title":["Papillomavirus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852116300696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852116300696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:03:00Z","timestamp":1762513380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405852116300696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":37,"alternative-id":["S2405852116300696"],"URL":"https:\/\/doi.org\/10.1016\/j.pvr.2017.03.001","relation":{},"ISSN":["2405-8521"],"issn-type":[{"value":"2405-8521","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence rates of Guillain Barr\u00e9 (GBS), chronic fatigue\/systemic exertion intolerance disease (CFS\/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002\u20132012","name":"articletitle","label":"Article Title"},{"value":"Papillomavirus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pvr.2017.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}